Diuretics are drugs that increase urine output by inhibiting ion transport mechanisms in the renal tubule, thereby reducing extracellular fluid volume and treating conditions such as hypertension, heart failure, and edema. They are classified according to their site of action along the nephron, which determines their potency and clinical applications.
What Are Diuretics?
The nephron reabsorbs the majority of filtered sodium and water, with different segments contributing varying proportions to total reabsorption. Diuretics target specific ion transporters along this pathway, producing natriuresis and diuresis proportional to the amount of sodium normally reabsorbed at that site. Understanding the site of action is essential for predicting diuretic efficacy, electrolyte effects, and clinical uses.
Mechanism of Action
Loop diuretics such as furosemide and bumetanide inhibit the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle, where approximately twenty-five percent of filtered sodium is reabsorbed. These are the most potent diuretics, producing substantial natriuresis even in patients with reduced renal function. They impair the kidney’s concentrating and diluting ability and increase calcium excretion.
Thiazide diuretics such as hydrochlorothiazide and chlorthalidone inhibit the sodium-chloride cotransporter in the distal convoluted tubule, where only five percent of filtered sodium is reabsorbed. They are less potent than loop diuretics but are effective antihypertensive agents with sustained duration of action. Thiazides reduce calcium excretion, which may benefit patients with calcium nephrolithiasis.
Potassium-sparing diuretics include aldosterone antagonists such as spironolactone and eplerenone, which competitively inhibit aldosterone receptors in the collecting duct, and epithelial sodium channel blockers such as amiloride and triamterene. These agents produce mild diuresis while conserving potassium, making them useful as add-on therapy to prevent hypokalemia and for specific indications such as primary hyperaldosteronism and heart failure.
Carbonic anhydrase inhibitors such as acetazolamide inhibit carbonic anhydrase in the proximal tubule, reducing bicarbonate reabsorption and producing a mild diuresis with alkaline urine. They are rarely used for diuresis today but have specific applications in glaucoma, altitude sickness, and metabolic alkalosis.
Therapeutic Uses
Loop diuretics are first-line therapy for acute and chronic heart failure with fluid overload and for edema in renal disease. Thiazides are first-line antihypertensive agents in many guidelines and are used for mild to moderate edema. Spironolactone improves outcomes in heart failure with reduced ejection fraction and is used for resistant hypertension. Combination therapy with loop and thiazide diuretics can overcome diuretic resistance.
Adverse Effects
Electrolyte and metabolic disturbances are the most common adverse effects. Loop and thiazide diuretics cause hypokalemia, hypomagnesemia, and metabolic alkalosis. Thiazides additionally cause hyperuricemia, hypercalcemia, glucose intolerance, and dyslipidemia. Potassium-sparing diuretics cause hyperkalemia, particularly when combined with ACE inhibitors or ARBs. Loop diuretics can cause ototoxicity, especially with rapid intravenous administration or high doses.
Contraindications
Diuretics are contraindicated in anuric patients and those with severe electrolyte abnormalities. Caution is required in patients with hepatic impairment, where rapid fluid shifts can precipitate encephalopathy. Thiazides are relatively contraindicated in patients with gout, and potassium-sparing diuretics should be avoided in patients with hyperkalemia or significant renal impairment.
Conclusion
Diuretics remain essential for managing fluid overload and hypertension. The choice of diuretic class depends on the severity of edema, renal function, electrolyte status, and comorbid conditions, with loop diuretics providing the most potent diuresis and thiazides serving as foundational antihypertensive therapy.
